HOOKIPA Pharma Current Ratio 2018-2021 | HOOK

HOOKIPA Pharma current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
HOOKIPA Pharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.14B $0.03B 4.24
2021-03-31 $0.15B $0.02B 7.62
2020-12-31 $0.17B $0.02B 8.11
2020-09-30 $0.11B $0.02B 5.65
2020-06-30 $0.12B $0.02B 6.35
2020-03-31 $0.12B $0.02B 7.85
2019-12-31 $0.13B $0.02B 8.68
2019-09-30 $0.14B $0.01B 10.53
2019-06-30 $0.15B $0.02B 8.69
2019-03-31 $0.09B $0.02B 5.63
2018-12-31 $0.06B $0.02B 4.24
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.129B $0.020B
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company. It is engaged in developing a class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform which is designed to reprogram the body's immune system. HOOKIPA Pharma Inc. is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86